<DOC>
	<DOC>NCT01930864</DOC>
	<brief_summary>MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.</brief_summary>
	<brief_title>Metformin Plus Irinotecan for Refractory Colorectal Cancer</brief_title>
	<detailed_description>MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine, irinotecan and anti-EGFr antibody if Kras wild type.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>18 years or older Biopsyproven colorectal adenocarcinoma Ineligibility for curative intent therapy, e.g., surgery or radiation Disease progression after oxaliplatin (either adjuvant or palliative), fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a antiEGFR therapy Assessable disease according to RECIST v1.1 known hypersensitivity to metformin or irinotecan CNS metastasis Acute or chronic severe infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>metformin</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>